IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
Recruiting · NCT07722494 · Registry updated 2026-08-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-08-10 | NCT07722494 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | 82 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Second Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou | China | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | China | 1 |